Centrum Medyczne Medyk Sp. z o.o. — Clinical Trial Site

43 Registered trials

11 Currently recruiting

Organisation

Centrum Medyczne Medyk Sp. z o.o.

Location

Rzeszow, Poland

Identifier

ORG-100032970

Address

Ul. Fryderyka Szopena 1, 35-055, Poland

Departments

"Centrum Medycznym Medyk Przychodnia Al. Rejtana 53"
#PL10001:Gastrology
3003:Cardiology
Centrum Medyczne „Medyk"
Centrum Medyczne Medyk
Centrum Medyczne Medyk Sp. z o.o.
Department of Oncology
Gastroenterologia
Gastroenterology
n/a
NA
Neurology
Pion Onkologiczny
PL10005: gastroenterology
PL10015: Centrum Medyczne Medyk
PL10016: Centrum Medyczne Medyk
PL10018:Centrum Medyczne MEDYK
PL10023_Gastroenterology
Poradnia neurologiczna
Private Practice
Szpital Centrum Medycznego Medyk

Clinical trials at this site (43)

Search interface

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP… Ended

2023-504998-20-00 Metastatic Hormone-sensitive Prostate Cancer Characteri 5 2020-09-18
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects … Ended

2023-505170-15-00 Adult Subjects With Late Onset Pompe Disease (LOPD) 5 2020-05-15
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended

2023-506429-13-00 Progressive multiple sclerosis (PMS) 5 2018-05-02
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30
REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended

2022-502677-42-00 Type 2 diabetes 5 2024-07-24
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended

2022-502778-18-00 ulcerative colitis 5 2023-11-17
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight… Ended

2022-502678-18-00 Type 2 diabetes 5 2023-11-07
A clinical study of the V116 vaccine for adults who have an increased risk for invasive pneumococcal disease Ended

2022-502791-22-01 Pneumococcal infection 5 2023-05-17
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29
A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended

2023-509741-12-00 Ulcerative Colitis 4 2021-09-23
Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA… Ended

2023-506961-74-00 Non-alcoholic steatohepatitis (NASH) 4 2021-08-31